Methods for Preparing Cord Matrix Stem Cells (CMSC) for Long Term Storage and for Preparing a Segment of umbilical cord for cryopreservation

• US 20090170059A1
• Filed: 11/14/2006
• Published: 07/02/2009
• Est. Priority Date: 11/14/2005
• Status: Abandoned Application

• Current Assignee: Tufts Medical Center Incorporated (Healthcare Realty Trust, Inc.)
• Original Assignee: Tufts Medical Center Incorporated (Healthcare Realty Trust, Inc.)
• Inventors: Klingemann, Hans
• Application Number:
  US12/084,931
• Publication Number:
  US 20090170059A1
• Time in Patent Office: Days
• US Class Current: 435/1.300
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0221 Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents

Abstract

Methods and kits are provided for preparation of umbilical cord fragments and cells using autologous blood or blood products, and for storage of these materials with autologous cells and blood or blood products in containers having a plurality of separable chambers.

Claims

1. A method for preparing cord matrix stem cells (CMSC) for cryopreserving, the method comprising contacting the CMSC with a cryoprotectant and cord blood serum or plasma, wherein the serum or plasma is obtained from a source autologous in origin to the CMSC, and wherein the CMSC are isolated from a plurality of locations along an entire circumference of a transverse section of an umbilical cord.

3. The method according to claim 1 wherein the cryoprotectant is selected from the group consisting of dimethyl sulfoxide, glycerol, ethylene glycol, and propylene glycol.

4. The method according to claim 1 wherein the source is human.

5. The method according to claim 1 further comprising, after obtaining the CMSC from the source, cryopreserving the CMSC without culturing the cells to expand the cell number.

6. The method according to claim 1 further comprising, prior to cryopreserving, expanding the CMSC cell number by culturing.

7. The method according to claim 6 wherein expanding the CMSC comprises culturing the cells for at least one day.

8. The method according to claim 6 wherein expanding the CMSC comprises culturing the cells for at least two days.

9. The method according to claim 1 wherein obtaining the CMSC further comprises, prior to cryopreserving, dissecting the cord to obtained resulting fragments, and isolating the CMSC from the fragments.

10. The method according to claim 9, wherein prior to isolating the CMSC, the fragments are cryopreserved.

11. The method according to claim 1, further comprising contacting the cord, blood and/or plasma using sterile technique, sterile apparatus, and sterile buffers, wherein the buffers are adjusted to physiological pH and osmolarity.

2. (canceled)

12. A method of cryopreserving, separately or together, a plurality of types of stem cells from a subject, the method comprising apportioning the stem cells into a separate chamber of a container comprising a plurality of chambers, wherein each of the chambers is separately accessible.

13. The method according to claim 12, wherein the types of stem cells are obtained from sources selected from the group consisting of cord, matrix, placenta, cord matrix stem cells (CMSC) and blood cells.

14. The method according to claim 12, wherein each of the stem cells is separately cryopreserved in a chamber within the same container.

15. The method according to claim 12, wherein the container is a plastic bag and the separated chambers are separable compartments of the bag.

17. The method according to claim 15, wherein the segments are less than about 2 cm in length.

18. The method according to claim 15, wherein the segments are less than about 1 cm in length.

19. The method according to claim 15, further comprising after cryopreserving, isolating cord matrix stem cells (CMSC) from the fragments.

20. The method according to claim 15, further comprising prior to dissecting, contacting the cord with sterile plasticware or glassware, and sterile buffer of physiological pH and osmolarity.

21. The method according to claim 15, wherein the segments comprise all or a portion of a circumferential transverse section of the cord.

22. The method according to claim 15 wherein the source is a mammal.

16. A method of preparing an umbilical cord obtained from an animal subject for cryopreservation, the method comprising:

preparing a plurality of segments of the cord;

dissecting each of the plurality of segments, wherein a plurality of resulting cord fragment preparations are obtained from each of the segments; and

cryopreserving separately each of the plurality of fragment preparations, wherein the umbilical cord is cryopreserved.

23. A kit comprising a plurality of chambers wherein each chamber contains at least one cryopreserved material selected from the group of cord matrix stem cells (CMSC) and cord blood cells, wherein the CMSC and cord blood cells are obtained from an autologous source, wherein the chambers comprise separate compartments attached within a container, and each chamber is separably accessible so that within each chamber are provided independently with respect to the remainder of the chambers.

25. The kit according to claim 23, wherein each chamber contains a unit dose of CMSC.

24. A kit comprising a plurality of chambers each chamber including cryopreserved cord matrix stem cells (CMSC) and/or cord blood cells, wherein the chambers comprise separate compartments attached within a plastic bag, wherein the CMSC and cord blood cells within each chamber are autologous, wherein each chamber is separately openable and wherein CMSC within each chamber are used independently with respect to the remainder of the chambers.

26. The kit according to claim 24, wherein CMSC and/or cord blood cells in the plurality of chambers are from an autologous source.

27. A method of increasing the number of hematopoietic cells, the method comprising:

transfecting at least one gene into feeder cells thereby improving ability of the feeder cells to serve as a feeder layer; and

culturing the hematopoietic cells with the feeder layer, wherein the number of hematopoietic cells is increased.

28. The method of claim 27, wherein culturing further comprises using a blood product that is autologous to the hematopoietic cells or the feeder cells.

29. The method according to claim 27, wherein the gene encodes at least one protein selected from the group consisting of granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage cell stimulating factor (GM-CSF), stem cell factor (SCF), thrombopoietin (TPO), erythropoietin (EPO), epidermal growth factor (EGF), keritinocyte growth factor (KGF), and other proteins that support the expansion and proliferation of cells.

30. The method according to claim 27, wherein the feeder cells are Wharton'"'"'s Jelly cells.

31. The method according to claim 27, wherein the hematopoietic cells are CD34⁺ hematopoietic progenitor cells.

32. The method according to claim 31, further comprising culturing the CD34⁺ hematopoietic progenitor cell and developing the cells into least one cell type selected from the group consisting of natural killer cells, T cells, and dendritic cells.

33. The method of claim 27 wherein the hematopoietic cells and the feeder cells are autologous.

34. A method of preparing feeder cells, the method comprising:

genetically manipulating feeder cells, wherein the genetic manipulating results in improving an ability of the feeder cells to serve as a feeder layer.

35. The method according to claim 34, wherein the feeder cells are genetically manipulated by transfecting genes into the feeder cells encoding at least one of granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage cell stimulating factor (GM-CSF), stem cell factor (SCF), thrombopoietin (TPO), erythropoietin (EPO), EGF, KGF, and other proteins that support the expansion and proliferation of cells.

36. The method according to claim 34, wherein prior to manipulating, the method comprises isolating the feeder cells from human umbilical cord.

37. The method according to claim 34, wherein isolating the feeder cells comprises obtaining Wharton'"'"'s Jelly cells.